MedTrace Logo

Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

NCT03822858 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-08-17

No results posted yet for this study

Summary

To give expanded access to intrathecal autologous MSC-NP treatment to patients with progressive MS who do not meet the inclusion/exclusion criteria of our Phase II stem cell trial.

Conditions

Interventions

DRUG

Intrathecal MSC-NP injection

Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose. 10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart.

Sponsors & Collaborators

  • Tisch Multiple Sclerosis Research Center of New York

    lead OTHER

Principal Investigators

  • Saud A Sadiq, MD, FAAN · Tisch MS Research Center of New York

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03822858 on ClinicalTrials.gov